Table 1

Characteristics of patients with biological heart prosthesis and adverse events during anticoagulant treatment

n612
Male (%)324 (52.9)
Median age (range)71.8 (24–89)
Total follow-up (patient-years)3085
Median follow-up (range)2.4 (0.5–7.5)
Indications for long-term anticoagulation, n (%)
 Atrial fibrillation480 (78.4)
 History of stroke/TIA13 (2.1)
 Cardiac diseases22 (3.6)
 Other indications for VKA6 (1.0)
 Unknown91 (14.8)
Clinical characteristics, n (%)
 Hypertension438 (71.6)
 Diabetes mellitus121 (19.8)
 Coronary artery disease-peripheral arteriopathy246 (40.2)
 Heart failure124 (20.3)
 Previous stroke/TIA77 (12.6)
 Antiplatelet treatment195 (31.9)
Adverse events, n (rate)
 Major bleeding34 (1.1)
 Stroke/TIA29 (0.9)
 Death36 (1.2)
  • TIA, transient ischaemic attack; VKA, vitamin k antagonist.